Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million financing commitment Management to host conference call today, May 8, 2024 , at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the first quarter ended March 31, 2024. “This was another tremendous quarter for Tarsus as we continued building a new category in eye care to serve millions of Demodex blepharitis patients with XDEMVY,” said Bobak Azamian, M.D., Ph.D., Chief Execu
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at HC Wainwright from $57.00 to $61.00. They now have a "buy" rating on the stock.MarketBeat
- Earnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their Estimates [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Barclays PLC from $50.00 to $60.00. They now have an "overweight" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare ConferenceGlobeNewswire
TARS
Earnings
- 5/8/24 - Beat
TARS
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 4/26/24 - Form ARS
- TARS's page on the SEC website